KURA ONCOLOGY, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
KURA ONCOLOGY, INC. (KURA) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $14.81 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2025-11-04
- KURA ONCOLOGY, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $12.72M, a 124.03% increase year-over-year.
- KURA ONCOLOGY, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-06-30 was $7.53M.
- KURA ONCOLOGY, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-03-31 was -$5.43M.
- KURA ONCOLOGY, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2024-12-31 was $12.70M, a 66.13% increase year-over-year.
- KURA ONCOLOGY, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $15.20M, a 47.19% increase from fiscal 2023.
- KURA ONCOLOGY, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $10.33M.
- KURA ONCOLOGY, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$802.00K.
- KURA ONCOLOGY, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2021 was -$2.52M, a 144.35% decline from fiscal 2020.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 1 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 4 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2025-09-30 | $12.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $20.24M derived: sum of 2 quarters · filed 2025-11-04 | $14.81M 10-Q · filed 2025-11-04 | $27.52M derived: sum of 4 quarters · filed 2025-11-04 | ||
| 2025-06-30 | $7.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.10M 10-Q · filed 2025-08-07 | $14.80M derived: sum of 3 quarters · filed 2025-08-07 | $20.48M derived: sum of 4 quarters · filed 2025-11-04 | ||
| 2025-03-31 | -$5.43M 10-Q · filed 2025-05-01 | $7.28M derived: sum of 2 quarters · filed 2025-05-01 | $12.95M derived: sum of 3 quarters · filed 2025-11-04 | $12.90M derived: sum of 4 quarters · filed 2025-11-04 | ||
| 2024-12-31 | $12.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $18.38M derived: sum of 2 quarters · filed 2025-11-04 | $18.33M derived: sum of 3 quarters · filed 2025-11-04 | $15.20M 10-K · filed 2025-02-28 | ||
| 2024-09-30 | $5.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $5.63M derived: sum of 2 quarters · filed 2025-11-04 | $2.50M 10-Q · filed 2025-11-04 | $10.14M derived: sum of 4 quarters · filed 2025-11-04 | ||
| 2024-06-30 | -$50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$3.18M 10-Q · filed 2025-08-07 | $4.47M derived: sum of 3 quarters · filed 2025-08-07 | $8.40M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | -$3.13M 10-Q · filed 2025-05-01 | $4.52M derived: sum of 2 quarters · filed 2025-05-01 | $8.45M derived: sum of 3 quarters · filed 2025-05-01 | $12.56M derived: sum of 4 quarters · filed 2025-05-01 | ||
| 2023-12-31 | $7.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $11.58M derived: sum of 2 quarters · filed 2025-02-28 | $15.69M derived: sum of 3 quarters · filed 2025-02-28 | $10.33M 10-K · filed 2025-02-28 | ||
| 2023-09-30 | $3.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $8.04M derived: sum of 2 quarters · filed 2024-11-07 | $2.68M 10-Q · filed 2024-11-07 | $1.12M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-06-30 | $4.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.25M 10-Q · filed 2024-08-08 | -$2.81M derived: sum of 3 quarters · filed 2025-02-28 | $3.54M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-03-31 | -$5.36M 10-Q · filed 2024-05-02 | -$6.92M derived: sum of 2 quarters · filed 2025-02-28 | -$574.00K derived: sum of 3 quarters · filed 2025-02-28 | -$915.00K derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2022-12-31 | -$1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $4.79M derived: sum of 2 quarters · filed 2025-02-28 | $4.45M derived: sum of 3 quarters · filed 2025-02-28 | -$802.00K 10-K · filed 2025-02-28 | ||
| 2022-09-30 | $6.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $6.01M derived: sum of 2 quarters · filed 2023-11-02 | $758.00K 10-Q · filed 2023-11-02 | $789.00K derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-06-30 | -$341.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$5.59M 10-Q · filed 2023-08-09 | -$5.56M derived: sum of 3 quarters · filed 2024-02-27 | -$5.42M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-03-31 | -$5.25M 10-Q · filed 2023-05-10 | -$5.22M derived: sum of 2 quarters · filed 2024-02-27 | -$5.08M derived: sum of 3 quarters · filed 2024-02-27 | -$6.32M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2021-12-31 | $31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $170.00K derived: sum of 2 quarters · filed 2024-02-27 | -$1.07M derived: sum of 3 quarters · filed 2024-02-27 | -$2.52M 10-K · filed 2024-02-27 | ||
| 2021-09-30 | $139.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$1.10M derived: sum of 2 quarters · filed 2022-11-03 | -$2.55M 10-Q · filed 2022-11-03 | $1.14M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-06-30 | -$1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$2.69M 10-Q · filed 2022-08-03 | $996.00K derived: sum of 3 quarters · filed 2023-02-23 | $3.53M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-03-31 | -$1.45M 10-Q · filed 2022-05-04 | $2.23M derived: sum of 2 quarters · filed 2023-02-23 | $4.76M derived: sum of 3 quarters · filed 2023-02-23 | $6.62M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2020-12-31 | $3.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $6.21M derived: sum of 2 quarters · filed 2023-02-23 | $8.07M derived: sum of 3 quarters · filed 2023-02-23 | $5.68M 10-K · filed 2023-02-23 | ||
| 2020-09-30 | $2.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $4.38M derived: sum of 2 quarters · filed 2021-11-04 | $1.99M 10-Q · filed 2021-11-04 | $4.08M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-06-30 | $1.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$537.00K 10-Q · filed 2021-08-05 | $1.55M derived: sum of 3 quarters · filed 2022-02-24 | $3.62M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-03-31 | -$2.39M 10-Q · filed 2021-05-06 | -$305.00K derived: sum of 2 quarters · filed 2022-02-24 | $1.76M derived: sum of 3 quarters · filed 2022-02-24 | $530.00K derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2019-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $4.16M derived: sum of 2 quarters · filed 2022-02-24 | $2.92M derived: sum of 3 quarters · filed 2022-02-24 | $856.00K 10-K · filed 2022-02-24 | ||
| 2019-09-30 | $2.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $835.00K derived: sum of 2 quarters · filed 2020-11-05 | -$1.23M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | -$1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$3.30M 10-Q · filed 2020-08-06 | ||||
| 2019-03-31 | -$2.06M 10-Q · filed 2020-05-04 | |||||
| 2018-12-31 | $5.12M 10-K · filed 2021-02-24 | |||||
| 2017-12-31 | $3.05M 10-K · filed 2020-02-25 | |||||
| 2015-12-31 | $251.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-17 | $1.43M derived: sum of 2 quarters · filed 2016-03-17 | $2.72M derived: sum of 3 quarters · filed 2016-03-17 | $2.81M 10-K · filed 2016-03-17 | ||
| 2015-09-30 | $1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $2.47M derived: sum of 2 quarters · filed 2015-11-13 | $2.56M 10-Q · filed 2015-11-13 | |||
| 2015-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $1.38M 10-Q · filed 2015-08-14 | ||||
| 2015-03-31 | $90.00K 10-Q · filed 2015-05-13 | |||||
| 2014-12-31 | $833.00K 10-K · filed 2016-03-17 | |||||
| 2014-09-30 | $60.00K 10-Q · filed 2015-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |